The pharma industry has called the IRA “price setting” and argues that the negotiations have not cut out-of-pocket costs for ...
The Delhi High Court on Tuesday dismissed Novo Nordisk's application to restrain Dr. Reddy's Laboratories Limited and ...
Some experts cited the case of Slentrol, an older weight loss drug for dogs made by Pfizer’s animal health division (which ...
Pharmaceuticals that mimic hormones now provide effective medical tools to combat obesity. Their long-term effects on society remain to be seen.
From surgery to supplements, GLP-1 medications are radically evolving the beauty space. We unpack the latest innovations.
Novo Nordisk lost billions in value because it failed to anticipate the risk posed by the introduction of its blockbuster ...
Patients and doctors are bracing as some major insurers get ready to roll out changes to coverage for popular weight loss drugs in Massachusetts. In January, companies including Blue Cross Blue Shield ...
The BrahMos missile was showcased at the recent Dubai Air Show, where it attracted substantial attention from potential ...
About valuation, the current forward P/E is 13, but that number only looks cheap because earnings are at an unsustainably ...
An oral version of the GLP-1 drug semaglutide failed to significantly slow the disease's progression compared to a placebo.
A pill version of Novo Nordisk A/S’s Ozempic failed to slow the progression of Alzheimer’s disease in a pair of high-risk ...
Scientists have failed to show that weight-loss wonder drug semaglutide slows the progress of Alzheimer's disease (AD), as ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback